Insider Transactions in Q1 2022 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2022
|
Prem S Shah EVP and Group President |
SELL
Open market or private sale
|
Direct |
5,346
-8.3%
|
$555,984
$104.7 P/Share
|
|
Mar 30
2022
|
Prem S Shah EVP and Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
5,346
+7.66%
|
$545,292
$102.26 P/Share
|
|
Mar 17
2022
|
Prem S Shah EVP and Group President |
SELL
Open market or private sale
|
Direct |
4,624
-3.76%
|
$490,144
$106.65 P/Share
|
|
Mar 17
2022
|
Prem S Shah EVP and Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,935
+4.52%
|
$305,240
$104.82 P/Share
|
|
Mar 15
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
51,361
+5.47%
|
$5,238,822
$102.26 P/Share
|
|
Mar 15
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
51,361
-5.78%
|
$5,392,905
$105.0 P/Share
|
|
Feb 28
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
436
-0.81%
|
$44,908
$103.65 P/Share
|
|
Feb 28
2022
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-0.23%
|
$14,523
$103.65 P/Share
|
|
Feb 26
2022
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,233
-34.92%
|
$544,232
$104.3 P/Share
|
|
Feb 26
2022
|
Michelle A Peluso EVP and Co-President of Retail |
SELL
Payment of exercise price or tax liability
|
Direct |
12,609
-45.82%
|
$1,311,336
$104.3 P/Share
|
|
Feb 26
2022
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
226
-0.38%
|
$23,504
$104.3 P/Share
|
|
Feb 21
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
171,944
+35.47%
|
-
|
|
Feb 21
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,595
+24.78%
|
-
|
|
Feb 21
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Grant, award, or other acquisition
|
Direct |
34,387
+37.34%
|
-
|
|
Feb 21
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
85,971
+36.85%
|
-
|
|
Feb 21
2022
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
257,916
+44.09%
|
-
|
|
Feb 21
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
787,472
+34.19%
|
-
|
|
Feb 21
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
322,395
+43.08%
|
-
|
|
Feb 21
2022
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
47,640
+44.42%
|
-
|
|
Feb 10
2022
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.17%
|
$105,000
$105.9 P/Share
|
|
Feb 03
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
47,937
-25.75%
|
$5,273,070
$110.0 P/Share
|
|
Feb 03
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,937
+20.48%
|
$4,889,574
$102.26 P/Share
|
|
Feb 01
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
21,386
-25.85%
|
$2,266,916
$106.5 P/Share
|
|
Feb 01
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
21,386
+20.54%
|
$2,181,372
$102.26 P/Share
|
|
Jan 28
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
6,059
-25.72%
|
$660,431
$109.0 P/Share
|
|
Jan 28
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,059
+20.46%
|
$618,018
$102.26 P/Share
|
|
Jan 27
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
68,482
-39.0%
|
$7,327,574
$107.5 P/Share
|
|
Jan 27
2022
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,482
+28.06%
|
$6,985,164
$102.26 P/Share
|